logo
Stocks on guard for payrolls, Tesla tumbles as Trump-Musk bromance sours

Stocks on guard for payrolls, Tesla tumbles as Trump-Musk bromance sours

Yahoo16 hours ago

By Stella Qiu
SYDNEY (Reuters) - Asian shares were subdued on Friday as investors hunkered down for the all-important payrolls report, while Tesla suffered huge losses on the very public feud between President Donald Trump and billionaire Elon Musk.
A run of soft economic data this week has markets wary of a downside surprise in the monthly payrolls print due later in the day, which would add to fears of stagflation while piling pressure on the Federal Reserve to ease policy in a hurry.
Tesla shares bounced 0.8% in after-hours trading after tumbling a whopping 14% overnight to wipe off $150 billion in market value. That came after Trump threatened to cut off government contracts to Elon Musk's companies as the once close relationship turned into a bitter public feud.
Nasdaq futures were flat and S&P 500 futures inched up 0.1%.
MSCI's broadest index of Asia-Pacific shares outside Japan slipped 0.1% on Friday but it is still set for a weekly rise of 2.2% to hover just below an eight-month peak.
Japan's Nikkei rose 0.3% but is set for a weekly drop of 0.7%.
South Korea's KOSPI is closed for a holiday but was up 4.2% this week to nearly 11-month tops as the newly elected President Lee Jae-myung planned an emergency package to boost the flagging economy. The won has also gained 2% this week to an eight-month peak.
Chinese blue chips were flat and Hong Kong's Hang Seng dropped 0.3% as a call between Trump and Chinese President Xi Jinping offered little clarity to ease ongoing trade tensions.
"The U.S.-China agreement to de-escalate tensions, and the recent phone call between Trump and Xi, shows both countries have an economic 'pain threshold'," said Luke Yeaman, chief economist at the Commonwealth Bank of Australia.
"This takes some severe downside scenarios off the table, but tensions will remain high and further bouts of escalation are likely...we see little prospect that a comprehensive US-China trade agreement will be settled by 14 August."
WAIT FOR PAYROLLS
Weaker-than-expected labour market data, including a 47% year-on-year jump in Challenger layoffs and a significant downside surprise in ADP's private payrolls, have dampened expectations for the payrolls report.
Forecasts are centred on a rise of 130,000 jobs in May, with the unemployment rate holding steady at 4.2%.
Any unexpected weakness could bring the next U.S. rate cut forward and trigger a huge rally in Treasuries. Futures imply scant chances of a rate cut until September, which is about 93% priced in, with another move likely to come in December.
Yields on the benchmark ten-year Treasuries were flat at 4.3925%, having risen 3 basis points overnight to bounce away from a one-month low.
"We expect payrolls to lose additional momentum in May, printing a below-consensus 110,000," said analysts at TD Securities in a note to clients.
"Markets have recently been singularly focused on tariffs and deficits, with macro taking a back seat in recent weeks. Our forecast may not be sufficient to catalyze this revamped focus on macro, but we expect downside surprises to generate a larger market reaction."
The dollar was flat against its major peers on Friday but was set for a weekly drop of 0.7% on soft economic data. [FRX/]
The euro got some support and hit a six-week top of $1.1495 overnight after the European Central Bank cut rates but signaled that it was nearing the end of its year-long policy easing cycle. Investors have given up on a move in July, with the final move mostly to come in December.
In commodities markets, oil prices were slightly lower but were headed for weekly gains on supply concerns. U.S. crude futures slipped 0.1% to $65.29 a barrel but was up 2.1% for the week. [FRX/]
In precious metals, gold prices climbed 0.3% to $3,362 an ounce. For the week, they are up 2.2%.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Mahmoud Khalil offers declaration, describes damages to his life
Mahmoud Khalil offers declaration, describes damages to his life

UPI

time10 minutes ago

  • UPI

Mahmoud Khalil offers declaration, describes damages to his life

June 6 (UPI) -- Mahmoud Khalil, the Columbia University graduate detained by the Trump administration in March for deportation over his pro-Palestinian views, offered a public declaration that details what he's experienced since his arrest. In a case document filed Thursday, Khalil listed what he described as the "irreparable harms" he has suffered, which he claimed have affected several parts of his life that "include dignitary and reputational harm, personal and familial hardship, including constant fear for personal safety, continued detention, restrictions on my freedom of expression, and severe damage to my professional future." The declaration, which was made from inside the LaSalle Detention Center in Jena, La., where Khalil has been held since March 9, puts focus on the birth of his son, which happened during his incarceration. "Instead of holding my wife's hand in the delivery room, I was crouched on a detention center floor, whispering through a crackling phone line as she labored alone." Khalil described. "I listened to her pain, trying to comfort her while 70 other men slept around me. When I heard my son's first cries, I buried my face in my arms so no one would see me weep." Khalil described that the first time he saw his son was through a window, and the first time he held him was in an immigration courtroom, to which his wife had to travel ten hours to reach, with their newborn. "I speak to her as often as possible, but these conversations are not private, everything is monitored by the government," Khalil said, which makes it impossible for them to comfortably speak freely. "We leave so much unsaid, and that silence weighs heavily on both of us." Khalil said that not only has the situation been "devastating" for him, but that his wife has dealt with harassment since his arrest. Khalil further described the anguish of seeing Trump administration officials post statements and photos of him on social media that he purports as "accompanied by inflammatory language, grotesque and false accusations, and open celebration of my deportation." Khalil expressed concern for his future as well. He said he was hired by the nonprofit equality-focused Oxfam International group only days before his arrest as a Palestine and Middle East/ North Africa policy advisor, and was scheduled to start work in April, but the job offer was formally revoked. He says "I strongly believe" his arrest and continued detention is the reason for this. He added that should the charges against him stand, "the harm to my professional career would be career-ending." Khalil further worried his arrest would result in a lifetime of "being flagged, delayed, or denied when traveling, applying for visas, or engaging with consular authorities anywhere in the world," and not just him, but his wife and son. His mother had also applied for a visa in March to visit the United States to see their child be born, and although that was approved, the U.S. embassy returned her passport without a stamp, and now her case is under "administrative processing," and remains unapproved. Khalil's elderly father, whom he describes as "severely disabled," lives in Germany, and he ponders whether any country allied with the United States will ever grant him entry should the charges stand. Khalil detailed the allegations under which he has been held for deportation, which not only did he deny as testimony at his May immigration court hearing, at which he purports "The government attorneys did not ask me any questions regarding these issues." However, Khalil maintained his greatest concern of all is a determination by Secretary of State Marco Rubio based on a law that an "alien" can be deported should his presence in the United States "have potentially serious adverse foreign policy consequences." "I understand that the Rubio Determination is not only a ground for deportation, but it is also a bar to entry," said Khalil. "In other words, no matter what happens to the other charge against me, it is the Rubio Determination that will make this country, the country of my wife and child, a country I cannot return to in the future."

3 Growth Companies With High Insider Ownership Achieving 101% Earnings Growth
3 Growth Companies With High Insider Ownership Achieving 101% Earnings Growth

Yahoo

time10 minutes ago

  • Yahoo

3 Growth Companies With High Insider Ownership Achieving 101% Earnings Growth

As the S&P 500 reaches new heights and investor confidence is bolstered by strong economic data, the focus on growth companies with high insider ownership becomes increasingly relevant. In today's market environment, stocks that combine robust earnings growth with significant insider investment can be particularly appealing, as they often signal strong internal confidence and alignment with shareholder interests. Name Insider Ownership Earnings Growth Super Micro Computer (SMCI) 16.2% 39.1% Ryan Specialty Holdings (RYAN) 15.5% 91% Prairie Operating (PROP) 34.2% 71.1% FTC Solar (FTCI) 27.9% 62.5% Enovix (ENVX) 12.1% 58.4% Eagle Financial Services (EFSI) 15.8% 82.8% Duolingo (DUOL) 14.3% 40% Credo Technology Group Holding (CRDO) 12.1% 45% Atour Lifestyle Holdings (ATAT) 22.7% 24.1% Astera Labs (ALAB) 15.1% 44.4% Click here to see the full list of 187 stocks from our Fast Growing US Companies With High Insider Ownership screener. Let's uncover some gems from our specialized screener. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Bridgewater Bancshares, Inc. is a bank holding company for Bridgewater Bank, offering various banking products and services in the United States with a market cap of $397.88 million. Operations: The company generates revenue primarily from its banking segment, amounting to $111.39 million. Insider Ownership: 20.6% Earnings Growth Forecast: 22.8% p.a. Bridgewater Bancshares exhibits strong growth potential with earnings forecasted to grow at 22.8% annually, outpacing the US market's 14.5%. Recent Q1 earnings showed net income rising to US$9.63 million from US$7.83 million year-over-year, indicating robust financial performance. However, insider activity reveals substantial selling over the past three months despite shares trading significantly below fair value estimates. The company also completed a share buyback of 3.29% for US$10.35 million, reflecting strategic capital management decisions. Dive into the specifics of Bridgewater Bancshares here with our thorough growth forecast report. The analysis detailed in our Bridgewater Bancshares valuation report hints at an deflated share price compared to its estimated value. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Organogenesis Holdings Inc. is a regenerative medicine company that develops, manufactures, and commercializes products for advanced wound care and surgical and sports medicine markets in the United States, with a market cap of $362.80 million. Operations: The company's revenue primarily comes from its regenerative medicine segment, which generated $458.76 million. Insider Ownership: 37.6% Earnings Growth Forecast: 101.7% p.a. Organogenesis Holdings is experiencing significant growth potential, with earnings forecasted to grow 101.69% annually and expected profitability within three years. Despite a volatile share price recently, the company trades at good value relative to peers. Recent Q1 results showed a decline in sales to US$86.69 million and an increased net loss of US$18.84 million year-over-year but reaffirmed its revenue guidance for 2025, projecting up to US$535 million in revenue with improved gross margins. Navigate through the intricacies of Organogenesis Holdings with our comprehensive analyst estimates report here. Our expertly prepared valuation report Organogenesis Holdings implies its share price may be lower than expected. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Viant Technology Inc. operates as an advertising technology company with a market cap of $864.67 million. Operations: The company generates revenue of $306.48 million from its Internet Information Providers segment. Insider Ownership: 12.2% Earnings Growth Forecast: 27.4% p.a. Viant Technology's earnings are forecast to grow significantly, outpacing the broader US market. Despite a recent net loss of US$1.19 million in Q1 2025, sales increased to US$70.64 million from the previous year. The company anticipates Q2 revenue between US$77 million and US$80 million. Trading well below its estimated fair value, analysts expect a stock price increase of 58.4%, highlighting potential for substantial growth despite current low return on equity projections. Unlock comprehensive insights into our analysis of Viant Technology stock in this growth report. The valuation report we've compiled suggests that Viant Technology's current price could be quite moderate. Click here to access our complete index of 187 Fast Growing US Companies With High Insider Ownership. Ready To Venture Into Other Investment Styles? Trump's oil boom is here — pipelines are primed to profit. Discover the 22 US stocks riding the wave. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years. Companies discussed in this article include BWB ORGO and DSP. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@

TG Therapeutics (NasdaqCM:TGTX) Stock Rises 13% In Last Month
TG Therapeutics (NasdaqCM:TGTX) Stock Rises 13% In Last Month

Yahoo

time11 minutes ago

  • Yahoo

TG Therapeutics (NasdaqCM:TGTX) Stock Rises 13% In Last Month

TG Therapeutics saw its share price rise by 13% last month. This period witnessed significant market fluctuations, such as the S&P 500 hitting 6,000 for the first time since February and strong job reports boosting economic sentiment. These positive macroeconomic developments likely provided a supportive backdrop for TG Therapeutics' stock performance. While specific corporate events for TG Therapeutics were not highlighted, broader economic trends, including subsiding tariff concerns and robust corporate earnings, may have indirectly influenced its upward price movement, complementing the overall positive sentiment in the equity markets. Be aware that TG Therapeutics is showing 1 warning sign in our investment analysis. This technology could replace computers: discover the 22 stocks are working to make quantum computing a reality. The recent surge in TG Therapeutics's share price, amid broader market positivity, aligns well with the company's growth narrative driven by the international expansion of BRIUMVI and ongoing trials. The positive economic environment has likely supported the stock's upward momentum, which could, in turn, positively impact revenue and earnings forecasts by enhancing investor sentiment and facilitating access to capital. Despite this short-term boost, it's important to consider that the long-term growth trajectory will depend heavily on successful execution of international expansion strategies and the outcome of ongoing clinical trials. Over the past three years, TG Therapeutics's impressive total return, including dividends, reached a very large percentage, providing substantial context for the current market enthusiasm. Notably, the company outperformed the US Market, which saw an 11% return over the last year, as well as the US Biotechs industry, which returned -12.1%, marking TG Therapeutics as a standout performer on both fronts. Compared to these benchmarks, the company's longer-term performance adds significant weight to its growth narrative. The price movement, in light of the analyst consensus price target of US$43.0, shows that TG Therapeutics's current share price is roughly in line with expectations, with only a small deviation indicating that the market sees the company as fairly valued at present. This alignment suggests that analysts' future expectations, particularly regarding revenue and earnings growth, are already factored into the current share price, underscoring the importance of delivering on those growth forecasts to maintain investor confidence. Dive into the specifics of TG Therapeutics here with our thorough balance sheet health report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqCM:TGTX. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store